Log in automatically

Log in | New user?


Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet (Business Wire)
yahoo.com     May 17, 2008            

RALEIGH, N.C.----Salix Pharmaceuticals, Ltd. today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.


Full Coverage:

Salix shares slide after FDA requests more data on drug

pharmiweb.co.uk     May 19, 2008          

slipped Monday after it was revealed that U.S. drug regulators want more information on one of the company's drugs before they will consider approving it for sale. Salix (Nasdaq: SLXP), the Raleigh pharmaceutical company, said late on May 16 that it has received an "approvable letter" from the...

analysis/comments

Salix Receives Approvable Letter for Ulcerative Colitis Drug

redorbit.com     May 19, 2008          

Posted on: Monday, 19 May 2008, 12:00 CDT Salix Pharmaceuticals has received an approvable letter from the FDA for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older. Bill Forbes, vice president of R&D and chief development...

analysis/comments

FDA asks for details on Salix drug

newsobserver.com     May 19, 2008          

Oil prices gain while pump prices rise to new high FDA asks for details on Salix drug By Sabine Vollmer, Staff Writer A gastrointestinal drug that could have bolstered Salix Pharmaceuticals' sales has come up short of regulatory approval. The balsalazide tablet is a stronger version of Colazal,...

analysis/comments

Salix shares slide after FDA requests more data on drug (at bizjournals.com)

yahoo.com     May 19, 2008          

slipped Monday after it was revealed that U.S. drug regulators want more information on one of the company's drugs before they will consider approving it for sale. Salix (Nasdaq: SLXP), the Raleigh pharmaceutical company, said late on May 16 that it has received an "approvable letter" from the...

analysis/comments

Salix Pharmaceuticals Receives Approvable Letter From FDA for Balsalazide Tablet

redorbit.com     May 18, 2008          

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.

analysis/comments

Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet

pharmiweb.co.uk     May 17, 2008          

RALEIGH, N.C. - (Business Wire) Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18...

analysis/comments

Salix Pharmaceuticals Receives Approvable Letter from FDA for

pharmiweb.co.uk     May 17, 2008          

Stocks mentioned in this article today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older. "Late this afternoon...

analysis/comments

Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet

finanznachrichten.de     May 17, 2008          

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older. “Late this...

analysis/comments

Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet

euroinvestor.co.uk     May 17, 2008          

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older. “Late this...

analysis/comments

Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet

finanzen.net     May 17, 2008          

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older. "Late this...

analysis/comments

1 2 next